Patrick Nemechek, D.O. – Published in The Journal of Emerging Diseases and Virology
OVERLAND PARK, KS, June 25, 2020 /24-7PressRelease/ — Nemechek Technologies, LLC announced the publication of a peer-reviewed article by Patrick Nemechek D.O. on the advantages of vagus nerve stimulation (VNS) as a candidate therapy for COVID-19. VNS is largely unrecognized as a therapeutic tool to regulate the cytokine storm in hospitalized patients.
Patients hospitalized with COVID-19 are predominantly dying of respiratory failure due to a surge of pro-inflammatory cytokines triggering acute respiratory distress syndrome (ARDS). ARDS is the reason such a high percentage of patients are requiring mechanical ventilation.
Dr. Nemechek notes that the solution to this deadly, unregulated immune response may be a mild electrical current applied to the vagus nerve. His method, known as transcutaneous auricular vagus nerve stimulation (taVNS), delivers this microcurrent through a specially designed clip that fits comfortably on the ear.
Stimulation of the afferent vagus nerve fibers in certain portions of the ear activates the inflammatory reflex which signals the body to block the production of these pro-inflammatory cytokines and naturally regulate the immune response. Human studies show that VNS is effective in suppressing the hyperimmune response in sepsis and improves clinical symptoms in several inflammatory pathologies. Additionally, animal studies suggest that VNS may also be capable of mitigating abnormal clotting seen in more severe COVID-19 patients.
taVNS is safe, non-invasive, portable, and does not interfere with other therapies. Importantly, a single taVNS device can be shared among many patients with minimum sterilization. The immediate goal of taVNS as a COVID-19 trial therapy is the urgent need to decrease ICU admissions, patient intubations, and deaths.
About Nemechek Technologies, LLC
Founded by Patrick Nemechek, D.O. and Jean Nemechek in 2019, Nemechek Technologies, LLC is a privately-held manufacturer of bio-electronic medicine. Their first product, the Vitality Smartcable, is the first taVNS neuromodulator that runs on your smartphone. Nemechek Technologies has offered to supply Vitality Smartcable devices for investigator-initiated clinical trials of taVNS therapy for COVID-19.
With 20 years’ experience as an HIV physician and researcher, Dr. Nemechek was awarded U.S. Patent No. 10,335,396 for his method of using vagus nerve stimulation to lower inflammation and reversing autonomic nervous system damage. The Nemechek Protocol®, which focuses on the reduction of chronic inflammation, includes the use of transcutaneous vagus nerve stimulation. Dr. Nemechek has treated more than 1,000 patients with vagus nerve stimulation therapy over the past ten years at his clinic near Phoenix, Ariz.
For the original version of this press release, please visit 24-7PressRelease.com here